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Summary
In a multicenter, randomized, controlled, open-label, par-
allel-group trial hyaluronic acid vaginal gel (Hya-
lofemme) was compared to estriol vaginal cream
(Ovestin) in women with vaginal dryness due to various
causes [1]. A total of 144 supposedly postmenopausal
women below age 70 years were randomized in a 1:1 ratio
to either receive hyaluronic acid vaginal gel (5 g per
application) or estriol vaginal cream (0.5 g cream per
application = 0.5 mg estriol) every 3 days for a total of ten
applications, respectively. Exclusion criteria included
vaginal infections, conventional contraindications to
estrogens, use of vaginal products other than the investi-
gational compounds, being unmarried, pregnant, or breast-
feeding. The aim of the study was to test for non-inferiority
of hyaluronic acid vaginal gel compared to estriol vaginal
cream. The primary efficacy end point was the percentage
(%) improvement in vaginal dryness, with the secondary
end points being the percentage (%) improvements in
vaginal itching, burning, and dyspareunia. Efficacy was
assessed by using a visual analog scale (VAS) (0–10;
0 = absent, 10 = intolerable) at baseline (V0), during
telephone contact after the third administration (V1), and at
the final visit after the tenth administration (V2). Safety
parameters included vaginal pH, endometrial thickness,
and a vaginal smear for vaginal microecosystem assess-
ment. Adverse events were recorded according to interna-
tional guidelines. 133 women completed the study. At
baseline, participants’ characteristics did not differ
significantly. Mean age was 54 years, time since meno-
pause was 5 years on average, and cause of menopause was
mostly natural. However, mean menstrual cycle days were
also reported, although according to inclusion criteria only
postmenopausal women were eligible for the study. At V1,
an improvement in vaginal dryness was reported by about
49 % of women using hyaluronic acid vaginal gel, and by
53 % of women using estriol vaginal cream (p = 0.31). At
V2, the percentage improvement rates were 84 and 89 %
(p = 0.13), respectively. Improvement rates for vaginal
itching, burning, and dyspareunia at V2 were about 86, 85,
and 57 % for hyaluronic acid vaginal gel, and 82, 87, and
62 % for estriol vaginal cream (p [ 0.05), respectively.
After treatment, vaginal pH was significantly lower in
estriol-treated women compared to those having received
hyaluronic acid. Endometrial thickness did not differ
between groups. In the majority of women, the vaginal
microenvironment remained unaffected by treatment.
However, the proportion of women whose abnormal vag-
inal microecological results became normal was higher in
women using estriol vaginal cream. Adverse events (sus-
pected to be) related to the investigational compounds were
minor and included vaginal infection and genital itching.
The authors concluded that hyaluronic acid vaginal gel was
not inferior to estriol vaginal cream in women presenting
with vaginal dryness. They suggest using hyaluronic acid
vaginal gel not only as an alternative treatment to vaginal
estrogens, but also to consider its general use in women
presenting with vaginal dryness of any cause.
Background
Vulvovaginal irritation is a frequent complaint among
postmenopausal women who do not use hormone therapy.
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Common symptoms of vaginal atrophy include dryness,
itching, burning, and dyspareunia [2]. The prevalence is up
to 45 % in midlife and older women [3]. In healthy vagina,
glycogen-derived glucose is converted into lactic acid
helping to maintain an acidic vaginal pH between 3.5 and
4.5. As estrogen-dependent glycogen content is gradually
lost during peri- and postmenopause, exfoliation of the
vaginal epithelium is decreased and leads to reduced nor-
mal lactobacilli flora and vaginal pH changes. The
increased vaginal pH and thinning of the vaginal epithe-
lium then increase the risk of mechanical weakness of the
vulvovaginal structures [2]. However, vaginal symptoms
may also be associated with the use of certain medications
(e.g. antidepressants, antihistamines), medical conditions
(e.g. diabetes mellitus, obesity, autoimmune disorders,
allergy), and lifestyle factors (e.g. smoking, excessive use
of soap, stress), respectively. Thus, also premenopausal
women may be affected. The North American Menopause
Society (NAMS) recently updated their recommendations
for the management of symptomatic vulvovaginal atrophy
(VVA) in postmenopausal women [4]. Nonprescription
therapies such as vaginal lubricants and moisturizers are
considered first-line therapies. In general (water, silicone,
or oil based), lubricants may be used during sexual inter-
course for reduction of friction-related irritation of atrophic
tissue. Additionally, nonhormonal, long-acting vaginal
moisturizing agents can decrease vaginal pH to premeno-
pausal levels, although they do not improve the vaginal
maturation index [4]. Hyaluronic acid is a glycosamino-
glycan and part of the extracellular matrix. Relative to its
molecular weight, it may bind huge amounts of water
making it a promising ingredient for a moisturizer. Indeed,
hyaluronic acid vaginal gel has been studied in postmen-
opausal women previously [5, 6]. Prescription therapies
such as low-dose vaginal estrogen therapy (ET) are con-
sidered second-line therapies. Internationally, there are
various approved ET products that are equally effective at
the recommended doses. The recommended dose for estriol
vaginal cream, for example, is 0.5 mg once daily during
the first 3 weeks, followed by 0.5 mg twice weekly. For a
new product to be approved for symptomatic VVA treat-
ment, pharmaceutical companies are recommended to fol-
low FDA guidance [7]. Herein, VVA is defined by the
following criteria: 5 % or less superficial cells on vaginal
smear (maturation index), vaginal pH[5.0, and at least one
moderate or severe symptom of VVA. The primary effi-
cacy analyses should demonstrate a statistically significant
improvement versus placebo from baseline to week 12 of
treatment in all three of the following parameters: (1)
maturation index (decrease of parabasal vaginal cells and
increase in superficial vaginal cells), (2) lowering of the
vaginal pH and (3) the moderate to severe symptom
identified by the subject as being most bothersome to her.
Comment
In the present study, the authors claim proving the non-
inferiority of hyaluronic acid vaginal gel compared to
estriol vaginal cream in women with vaginal dryness.
However, there are some flaws in the study design, thus
hampering this conclusion. First, with respect to the study
population, given the menstrual cycle data reported, pre-
menopausal women of unknown number seem to have been
included into the study, although per protocol only post-
menopausal women were eligible. Inclusion criteria did not
request a predefined lower threshold of vaginal symptom
intensity. Thus, also women with minor symptom intensity
were eligible. Dyspareunia is an important end point in
studies investigating vaginal products. However, it is cru-
cial to assess the prevalence and frequency of sexual
activity in participants at baseline and across the study;
otherwise, no conclusion regarding improvement in dys-
pareunia can be drawn. Furthermore, various other reasons
are known to be related to vaginal symptoms that have not
been assessed. Taken together, the study population was
very heterogenous. Secondly, with respect to the study
design, a randomized-controlled, double-blind trial would
have been preferable to reduce bias. According to FDA, the
primary efficacy end point should involve vaginal pH,
vaginal maturation index and the most bothersome mod-
erate to severe vaginal symptom [7]. In the present study,
the primary efficacy end point was subjective, whereas
vaginal pH was assessed as safety parameter only. Statis-
tical analysis revealed no between-group differences for
any VAS symptom score at V1 and V2, respectively.
However, p values for pre-/post-treatment comparisons
within each group were not provided. During follow-up at
V1 and V2, the number of missing data was quite high. For
example, at V2, data of only 40 % of the participants using
hyaluronic acid vaginal gel and of 53 % women using
estriol vaginal cream were available for statistical analysis
with respect to the symptom of vaginal itching. Of course,
missing data could also mean that these women did not
present with the symptom at baseline, making a compari-
son between V0, V1, and V2 impossible. Finally, with
respect to the intervention, the application modus for
hyaluronic acid vaginal gel corresponded to the general
recommendation. However, this is not true for estriol
vaginal cream. In addition, ten applications in total are
usually not sufficient to prove the efficacy for symptomatic
VVA treatment, at least in postmenopausal women [7].
In conclusion, due to the limitations mentioned, the
present study does not prove the general non-inferiority of
hyaluronic acid vaginal gel in comparison to estriol vaginal
cream in women with vaginal dryness. However, due to a
previous placebo-controlled study and since no major side
effects are to be expected with the use of hyaluronic acid
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vaginal gel, it may be used as moisturizer in women com-
plaining of vaginal dryness. This treatment strategy is thus
in accordance with the updated NAMS recommendations.
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